pNF-H Has Potential As Biomarker of Spinal Muscular Atrophy Disease Activity
April 24th 2019Infants with SMA—who have elevated pNF-H levels—experienced significant drops in pNF-H levels when treated with nusinersen (Spinraza, Biogen), suggestive of pNF-H’s potential as a biomarker of disease activity and treatment response.
Teva Halts Clinical Development of Fremanezumab for Cluster Headache
April 23rd 2019A prespecified futility analysis of a phase 3 study revealed that the primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met.
Eptinezumab Endeavors to Maintain Migraine Prevention Progress
April 23rd 2019The chief executive officer of Alder Biopharmaceuticals detailed where the intravenous anti-CGRP treatment will fit into the marketplace and how the migraine prevention therapy will make an impact in treating patients.
New Acute Migraine Co-Primary End Points Provide Positives for Trial Design
April 22nd 2019A review of newly implemented primary end points—pain freedom and most bothersome symptom freedom at 2 hours—used in 8 clinical trials may help to guide future migraine researchers in the design of acute treatment trials.
Integrative Health and Parkinson Disease
April 18th 2019It has been estimated that between 40% and 60% of patients with PD use at least one form of complementary medicine. In this podcast, neurologist Sarah Mulukutla, MD, MPH talks about CAM options for neurologists to discuss with their patients.
Adverse Pregnancy Outcomes in Teriflunomide-Exposed MS Patients Similar to General Population
April 17th 2019Patients with multiple sclerosis who were exposed to teriflunomide during pregnancy experienced similar risks of major birth defects and spontaneous abortions to the general population’s rates of 2% to 4% and 15% to 20%, respectively.
FDA Accepts NDA for Riluzole Oral Film for ALS
April 16th 2019The Aquestive Therapeutics product, marketed as Exservan, was previously granted an orphan drug designation in January 2018. Its NDA is supported by a number of studies which sought to confirm its bioequivalence to its reference listed drug.
Erenumab Efficacious In Episodic Migraine Patients With Prior Treatment Failure
April 16th 2019The study also added to a growing base of findings which suggest that patients who have failed preventive medications prior to trial participation have lower placebo responses, which could have implications for clinical trial design.
Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis Diagnosis
April 16th 2019The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke spoke about the potential of the central vein sign to help improve the time to an accurate diagnosis in MS.